Vertex Pharmaceuticals has long been synonymous with Cystic Fibrosis treatment. But with the company's aggressive expansion into new therapeutic areas, is it ready to leave its CF-centric identity behind? This podcast discusses Vertex's diversification strategy, analyzing its potential to become a multi-disease-focused pharmaceutical company, and the challenges it faces in doing so.
For informational and entertainment purposes only—not formal financial advice.
